MA46750A - Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents - Google Patents
Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agentsInfo
- Publication number
- MA46750A MA46750A MA046750A MA46750A MA46750A MA 46750 A MA46750 A MA 46750A MA 046750 A MA046750 A MA 046750A MA 46750 A MA46750 A MA 46750A MA 46750 A MA46750 A MA 46750A
- Authority
- MA
- Morocco
- Prior art keywords
- ralinepag
- agents
- combinations
- methods
- treating pah
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420515P | 2016-11-10 | 2016-11-10 | |
| US201762530533P | 2017-07-10 | 2017-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46750A true MA46750A (fr) | 2019-09-18 |
Family
ID=60451197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046750A MA46750A (fr) | 2016-11-10 | 2017-11-10 | Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12377067B2 (https=) |
| EP (2) | EP4681708A3 (https=) |
| JP (3) | JP2019533713A (https=) |
| KR (4) | KR20260020212A (https=) |
| CN (2) | CN110691612B (https=) |
| AU (3) | AU2017357759A1 (https=) |
| CA (1) | CA3043283A1 (https=) |
| ES (1) | ES3052035T3 (https=) |
| IL (2) | IL266518B1 (https=) |
| MA (1) | MA46750A (https=) |
| WO (1) | WO2018089804A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260020212A (ko) | 2016-11-10 | 2026-02-10 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
| EP3977985B1 (en) | 2017-03-01 | 2023-09-06 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| WO2019222764A1 (en) * | 2018-05-16 | 2019-11-21 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| CN108721296B (zh) * | 2018-07-03 | 2019-04-05 | 中国人民解放军总医院 | 一种化合物在治疗或预防高原病中的用途 |
| CN112638865B (zh) * | 2018-09-06 | 2022-07-26 | 广东东阳光药业有限公司 | 药物共晶体及其制备方法 |
| CA3123990A1 (en) * | 2018-12-21 | 2020-06-25 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| US20230263807A1 (en) * | 2022-02-08 | 2023-08-24 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| US12098116B2 (en) | 2022-02-15 | 2024-09-24 | United Therapeutics Corporation | Crystalline prostacyclin (IP) receptor agonist and uses thereof |
| US20250282716A1 (en) | 2024-03-11 | 2025-09-11 | United Therapeutics Corporation | Methods of making ip-receptor agonists |
| CN121714543A (zh) * | 2024-09-23 | 2026-03-24 | 上海欣药智能科技有限公司 | 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途 |
| US12582629B1 (en) * | 2025-10-23 | 2026-03-24 | Innovate Therapeutics Llc | Extended-release pharmaceutical compositions of Ralinepag |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085844A1 (en) | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| WO2002055484A1 (en) | 2001-01-12 | 2002-07-18 | Takeda Chemical Industries, Ltd. | Biaryl compound, process for producing the same, and agent |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TWI293715B (en) | 2002-10-10 | 2008-02-21 | Sipix Imaging Inc | A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display |
| CN101723891A (zh) | 2003-02-10 | 2010-06-09 | 沃泰克斯药物股份有限公司 | 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法 |
| GB0325291D0 (en) | 2003-10-29 | 2003-12-03 | Pfizer Ltd | Novel combination |
| US20060063930A1 (en) | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
| WO2007051255A1 (en) | 2005-11-04 | 2007-05-10 | The University Of Sydney | Process for the preparation of compounds containing an azacyclic ring system |
| CN101489544A (zh) | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
| KR20230085944A (ko) * | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
| JP5603343B2 (ja) | 2008-11-26 | 2014-10-08 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連する障害を処置するために有用なプロスタサイクリン（ｐｇｉ２）受容体モジュレーターとしてのピラゾリル置換炭酸誘導体 |
| PT2370413E (pt) | 2008-12-08 | 2015-10-23 | Arena Pharm Inc | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo |
| EP2480526A1 (en) * | 2009-09-23 | 2012-08-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| US9388154B2 (en) | 2011-09-12 | 2016-07-12 | Lund Biotechnology PBC | Process for preparing synthetic prostacyclins |
| AU2013351934B2 (en) * | 2012-11-30 | 2018-03-29 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| WO2016065103A1 (en) * | 2014-10-23 | 2016-04-28 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the pgi2 receptor |
| EP3244968B1 (en) * | 2015-01-13 | 2023-08-30 | Vivus LLC | Combination therapy for pulmonary hypertension |
| KR20260020212A (ko) | 2016-11-10 | 2026-02-10 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
-
2017
- 2017-11-10 KR KR1020267001774A patent/KR20260020212A/ko active Pending
- 2017-11-10 US US16/348,665 patent/US12377067B2/en active Active
- 2017-11-10 JP JP2019524887A patent/JP2019533713A/ja active Pending
- 2017-11-10 CN CN201780082981.0A patent/CN110691612B/zh active Active
- 2017-11-10 CN CN202411493404.9A patent/CN119367341A/zh active Pending
- 2017-11-10 CA CA3043283A patent/CA3043283A1/en active Pending
- 2017-11-10 EP EP25199189.9A patent/EP4681708A3/en active Pending
- 2017-11-10 MA MA046750A patent/MA46750A/fr unknown
- 2017-11-10 KR KR1020247014676A patent/KR102916884B1/ko active Active
- 2017-11-10 ES ES17804042T patent/ES3052035T3/es active Active
- 2017-11-10 WO PCT/US2017/061116 patent/WO2018089804A1/en not_active Ceased
- 2017-11-10 KR KR1020197016623A patent/KR20200015439A/ko not_active Abandoned
- 2017-11-10 AU AU2017357759A patent/AU2017357759A1/en not_active Abandoned
- 2017-11-10 EP EP17804042.4A patent/EP3538154B1/en active Active
- 2017-11-10 KR KR1020237003653A patent/KR20230021186A/ko not_active Abandoned
-
2019
- 2019-05-08 IL IL266518A patent/IL266518B1/en unknown
-
2022
- 2022-11-21 JP JP2022185917A patent/JP2023029865A/ja active Pending
-
2023
- 2023-11-09 AU AU2023263497A patent/AU2023263497C1/en active Active
-
2025
- 2025-05-20 JP JP2025084398A patent/JP2025131627A/ja active Pending
- 2025-06-20 US US19/244,745 patent/US20260014114A1/en active Pending
- 2025-09-14 IL IL323354A patent/IL323354A/en unknown
- 2025-12-16 AU AU2025283444A patent/AU2025283444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3052035T3 (en) | 2025-12-30 |
| CN110691612A (zh) | 2020-01-14 |
| KR20260020212A (ko) | 2026-02-10 |
| JP2019533713A (ja) | 2019-11-21 |
| KR20200015439A (ko) | 2020-02-12 |
| AU2023263497C1 (en) | 2026-01-22 |
| AU2017357759A1 (en) | 2019-06-06 |
| EP4681708A3 (en) | 2026-03-18 |
| AU2025283444A1 (en) | 2026-01-15 |
| CA3043283A1 (en) | 2018-05-17 |
| JP2023029865A (ja) | 2023-03-07 |
| US20190321328A1 (en) | 2019-10-24 |
| EP3538154A1 (en) | 2019-09-18 |
| WO2018089804A1 (en) | 2018-05-17 |
| US12377067B2 (en) | 2025-08-05 |
| US20260014114A1 (en) | 2026-01-15 |
| IL266518B1 (en) | 2026-01-01 |
| CN110691612B (zh) | 2024-11-08 |
| KR20230021186A (ko) | 2023-02-13 |
| KR20240068077A (ko) | 2024-05-17 |
| WO2018089804A9 (en) | 2018-06-21 |
| AU2023263497B2 (en) | 2025-09-18 |
| CN119367341A (zh) | 2025-01-28 |
| IL323354A (en) | 2025-11-01 |
| AU2023263497A1 (en) | 2023-11-30 |
| JP2025131627A (ja) | 2025-09-09 |
| IL266518A (en) | 2019-07-31 |
| KR102916884B1 (ko) | 2026-01-22 |
| EP3538154B1 (en) | 2025-09-03 |
| EP4681708A2 (en) | 2026-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46750A (fr) | Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents | |
| EP3668500A4 (en) | METHOD OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL | |
| EP3226848A4 (en) | METHOD FOR TREATING ALOPECIA AREATA USING GENE MODULATION APPARATUS | |
| EP3471780A4 (en) | TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
| EP3436052A4 (en) | TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES | |
| EP3436020A4 (en) | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS | |
| EP3340971A4 (en) | METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE | |
| MA42450A (fr) | Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie | |
| EP3426286A4 (en) | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN | |
| EP3512524A4 (en) | METHOD AND COMPOSITIONS FOR TREATING VIRUS INFECTIONS | |
| EP3423100A4 (en) | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF | |
| EP3302379A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM | |
| EP3432891A4 (en) | METHOD FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE | |
| EP3285776A4 (en) | METHOD FOR TREATING BACTERIAL INFECTIONS | |
| EP3519058C0 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR | |
| EP3405191A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS | |
| EP3426777A4 (en) | COMBINATION VECTORS AND METHOD FOR THE TREATMENT OF CANCER | |
| EP3503904A4 (en) | ASCAROSIDE TREATMENT OF EOSINOPHILER OESOPHAGITIS | |
| EP3458079A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ACNE | |
| MA46967A (fr) | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
| MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
| EP3400008A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEPATITIS B |